carlo albera
carlo albera
Professore Associato di Malattie dell'Apparato Respiratorio
Verified email at unito.it
Title
Cited by
Cited by
Year
Idiopathic pulmonary fibrosis
TE King Jr, A Pardo, M Selman
The Lancet 378 (9807), 1949-1961, 2011
1944*2011
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
PW Noble, C Albera, WZ Bradford, U Costabel, MK Glassberg, ...
The Lancet 377 (9779), 1760-1769, 2011
14302011
Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement
RP Baughman, M Drent, M Kavuru, MA Judson, U Costabel, R du Bois, ...
American journal of respiratory and critical care medicine 174 (7), 795-802, 2006
5962006
Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial
TE King Jr, C Albera, WZ Bradford, U Costabel, P Hormel, L Lancaster, ...
The Lancet 374 (9685), 222-228, 2009
4972009
Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.
RM du Bois, D Weycker, C Albera, WZ Bradford, U Costabel, A Kartashov, ...
3442011
Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis
RM du Bois, D Weycker, C Albera, WZ Bradford, U Costabel, A Kartashov, ...
American journal of respiratory and critical care medicine 184 (4), 459-466, 2011
3342011
Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference
RM Du Bois, D Weycker, C Albera, WZ Bradford, U Costabel, A Kartashov, ...
American journal of respiratory and critical care medicine 184 (12), 1382-1389, 2011
3332011
Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials
PW Noble, C Albera, WZ Bradford, U Costabel, RM Du Bois, EA Fagan, ...
European Respiratory Journal 47 (1), 243-253, 2016
2202016
Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis
SD Nathan, C Albera, WZ Bradford, U Costabel, I Glaspole, MK Glassberg, ...
The Lancet Respiratory Medicine 5 (1), 33-41, 2017
1342017
6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis
RM du Bois, C Albera, WZ Bradford, U Costabel, JA Leff, PW Noble, ...
European Respiratory Journal 43 (5), 1421-1429, 2014
1182014
Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis
MA Judson, RP Baughman, U Costabel, M Drent, KF Gibson, G Raghu, ...
European Respiratory Journal 44 (5), 1296-1307, 2014
1162014
Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with …
SD Nathan, C Albera, WZ Bradford, U Costabel, RM Du Bois, EA Fagan, ...
Thorax 71 (5), 429-435, 2016
1122016
An open-label, phase II study of the safety and tolerability of pirfenidone in patients with scleroderma-associated interstitial lung disease: the LOTUSS trial
D Khanna, C Albera, A Fischer, N Khalidi, G Raghu, L Chung, D Chen, ...
The Journal of rheumatology 43 (9), 1672-1679, 2016
1062016
All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials
TE King Jr, C Albera, WZ Bradford, U Costabel, RM du Bois, JA Leff, ...
American journal of respiratory and critical care medicine 189 (7), 825-831, 2014
992014
Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function
C Albera, U Costabel, EA Fagan, MK Glassberg, E Gorina, L Lancaster, ...
European Respiratory Journal 48 (3), 843-851, 2016
922016
Comprehensive assessment of the long‐term safety of pirfenidone in patients with idiopathic pulmonary fibrosis
D Valeyre, C Albera, WZ Bradford, U Costabel, TE King Jr, JA Leff, ...
Respirology 19 (5), 740-747, 2014
922014
Repopulation of human pulmonary epithelium by bone marrow cells: a potential means to promote repair
C Albera, JM Polak, S Janes, MJD Griffiths, MR Alison, NA Wright, ...
Tissue engineering 11 (7-8), 1115-1121, 2005
902005
Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials
L Lancaster, C Albera, WZ Bradford, U Costabel, RM Du Bois, EA Fagan, ...
BMJ open respiratory research 3 (1), e000105, 2016
822016
Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial
J Behr, E Bendstrup, B Crestani, A Günther, H Olschewski, CM Sköld, ...
The Lancet Respiratory Medicine 4 (6), 445-453, 2016
792016
Hot of the breath: mortality as a primary end-point in IPF treatment trials: the best is the enemy of the good
AU Wells, J Behr, U Costabel, V Cottin, V Poletti, L Richeldi
Thorax 67 (11), 938-940, 2012
682012
The system can't perform the operation now. Try again later.
Articles 1–20